 |
SK Plasma |
[Alpha Biz= Reporter Kim Sangjin] SK Plasma, a leading blood product company, has successfully secured investment from Indonesia's sovereign wealth fund (INA) for the operation of its joint venture in the country.
On the 14th of this month, SK Plasma (CEO: Kim Seung-joo) announced that it had signed an investment confirmation agreement with INA for the operation of the joint venture, SK Plasma Core Indonesia (SK Plasma Core). The agreement follows a memorandum of understanding (MOU) signed in October of last year to establish a blood plasma facility in Indonesia, where the INA will acquire a significant share in SK Plasma Core, making it the second-largest shareholder.
This deal marks the first instance of a South Korean company attracting investment from INA. It highlights SK Plasma's proven expertise in managing blood plasma plants and its technological capabilities, as well as the Indonesian government's strong commitment to achieving self-sufficiency in blood products.
SK Plasma has secured business rights from the Indonesian Ministry of Health and is moving forward with the construction of the blood plasma plant through the joint venture. The new plant, scheduled to begin operations in the fourth quarter of 2026, will be located in the Karawang Industrial Complex on a site spanning approximately 49,000 square meters. The plant is expected to process 600,000 liters of plasma annually to produce blood products, including albumin and immunoglobulin.
Alphabiz Reporter Kim SangJin(letyou@alphabiz.co.kr)
